Successful resection after first‐line lenvatinib therapy in an advanced thymic carcinoma

Thymic carcinoma is a highly malignant tumor and treatment options are limited. Lenvatinib, a novel multitargeted kinase inhibitor, has recently been approved for the treatment of unresectable thymic carcinoma. There are no reports of complete surgical resection after the administration of first‐lin...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimura, Masatoshi, Miura, Kentaro, Koizumi, Tomonobu, Kanda, Shintaro, Mishima, Shuji, Hara, Daisuke, Matsuoka, Shunichiro, Eguchi, Takashi, Hamanaka, Kazutoshi, Uehara, Takeshi, Shimizu, Kimihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260480/
https://www.ncbi.nlm.nih.gov/pubmed/37132133
http://dx.doi.org/10.1111/1759-7714.14913

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260480/
https://www.ncbi.nlm.nih.gov/pubmed/37132133
http://dx.doi.org/10.1111/1759-7714.14913

Ejemplares similares